|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1995-03-31 |
|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
Randomized, Multicenter, Observer-Masked Study to Compare Safety/Efficacy of Nebivolol Suspension 0.5% or 1.0%, or Timolol Suspension 0.5% to Timolol Solution 0.5% in Participants With Primary Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety (in the eye and throughout the body) and effectiveness of nebivolol (0.5 and 1 percent) and timolol (0.5 percent) eye drop suspensions. These eye drops will be compared to timolol 0.5 percent eye drop solution in participants with open angle glaucoma (the most common type of glaucoma) or high eye pressure (ocular hypertension).
100 项与 Betaliq, Inc. 相关的临床结果
0 项与 Betaliq, Inc. 相关的专利(医药)
100 项与 Betaliq, Inc. 相关的药物交易
100 项与 Betaliq, Inc. 相关的转化医学